Actively Recruiting
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Led by UConn Health · Updated on 2025-08-12
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
UConn Health
Lead Sponsor
C
CT Department of Public Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research focuses on understanding the role of two proteins in the blood that may increase during acute heart failure, a condition where the heart cannot contract properly. The study aims to explore the relationship between changes in these proteins and the occurrence of acute heart failure, as current markers like BNP are not reliable predictors for the transition from stable to worsening heart failure. It highlights the importance of early detection and prevention in managing heart failure, which affects millions and leads to many hospital admissions and deaths annually. The study observes levels of activated caspase-3 and dystrophin, proteins linked to heart muscle cell death and structural support, respectively. It will measure these proteins and other inflammatory markers like IL-6, TNF alpha, and CRP in patients with stable or acute decompensated heart failure and healthy controls. Blood samples will be taken every three months for two years to track changes and assess whether spikes in these markers predict adverse outcomes. Participants will have their blood tested regularly, and researchers will monitor hospitalizations for acute heart failure, heart attacks, strokes, or death over three years. The study will also look for daily rhythm changes and serial variations of these proteins to better understand their role. Healthy volunteers without heart disease will be included as controls. The goal is to identify markers that could help predict and manage heart failure progression more proactively.
CONDITIONS
Brief Title
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals aged over 18 years
- Stable or decompensated heart failure, regardless of left ventricular ejection fraction
- Presence of clinical symptoms of decompensated heart failure such as shortness of breath, lung crackles, swelling, elevated neck vein pressure, or abdominal fluid
- Imaging evidence of heart failure, including enlarged heart, poor heart contraction, diastolic dysfunction, or elevated heart filling pressures
- Healthy individuals with no history of heart attack or heart failure may be included as controls
You will not qualify if you...
- Unable to provide informed consent
- Cardiac or non-cardiac surgery within 3 months before enrollment
- Pregnancy is not excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants with stable or decompensated heart failure, as well as healthy control individuals, have blood samples collected every 3 months to measure circulating markers related to heart failure progression and other inflammatory markers. This monitoring aims to identify changes that may predict adverse outcomes.
Quarterly visits for up to 2 years
Trial Site Locations
Total: 1 location
1
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Actively Recruiting
Research Team
F
Fahad E Shah
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here